Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of UTTR1147A in Healthy Volunteers and Patients with UC or CD
NCT02749630Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2016
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of efmarodocokin alfa in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events. Started Apr 2016; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02749630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749630.